Jan 10, 2022 / 08:00PM GMT
Christopher Z. Neyor - JPMorgan Chase & Co, Research Division - Analyst
Good morning, everyone. I'm Chris here from the biopharma team at JPMorgan. It's my pleasure to be introducing Pacira BioSciences. From the company, we have CEO, David Stack. (Operator Instructions) With that, I'll hand it over to Dave. Happy New Year, and thanks for joining us.
David M. Stack - Pacira BioSciences, Inc. - Chairman & CEO
Thank you, Christopher, and thank you to JPMorgan for the opportunity to spend a few minutes with you this afternoon. Any other disclosures can be found on the Pacira website. So Pacira has developed a portfolio of unique, safe, best-in-class products, which act along the patient's neural pathway to treat postsurgical pain, acute and chronic arthritis pain, spasticity as well additional unmet medical needs. As you can see on the slide, we have very large target addressable market opportunities with all of our products.
We believe that this unique portfolio allows us the opportunity to sell this suite of products to the same target audiences.
Pacira Biosciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers